➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Merck
McKesson
Mallinckrodt
Harvard Business School
Johnson and Johnson

Last Updated: September 21, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR HUMATROPE

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Humatrope

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00190658 ↗ Somatropin Treatment in Patients With SHOX Deficiency and Turner Syndrome Completed Eli Lilly and Company Phase 3 2000-02-01 This clinical trial will compare the mean first year height velocity of somatropin-treated prepubertal patients with SHOX deficiency with the height velocity of a control group of untreated prepubertal patients with SHOX deficiency. Both groups will be compared to a somatropin-treated group of girls with Turner syndrome. After the second year patients in the control group have the option to receive treatment as well. All patients will optionally be treated until they achieved adult height.
NCT00191074 ↗ Amendment (g) Unblinded Extension Phase of Somatropin in Patients With Idiopathic Short Stature Completed Eli Lilly and Company Phase 3 2001-02-01 After approval of amendment (g), patients who were still receiving study drug at the time were scheduled for a study visit. In addition, patients who had discontinued early from the core, blinded phase of the study were contacted. All of these patients were offered the opportunity to enter the unblinded extension phase (if they met eligibility criteria) and continue somatropin treatment (regardless of initial treatment randomization) until they reached final height.
NCT00191113 ↗ Somatropin Treatment to Final Height in Turner Syndrome Completed Eli Lilly and Company Phase 3 1989-02-01 A randomized, controlled trial in girls with Turner syndrome at least 7 years old and younger than 13 at study entry, to determine the efficacy and safety of Humatrope (somatropin) treatment in promoting linear growth to final height.
NCT00191165 ↗ Efficacy and Safety of a High Dosage Compared to the Label Dosage of Somatropin in Early Pubertal Stage Children With Growth Hormone Deficiency Completed Eli Lilly and Company Phase 3 2004-03-01 Multi-center, randomized, controlled, open-label, phase III study comparing the effects of two different dosages of somatropin treatment (in-label or doubled) after 12 and 24 months of treatment, on height velocity in early pubertal children with growth hormone deficiency (GHD). The study will be conducted in Italy. Approximately 26 subjects will participate in this study, distributed as 13 in the in-label dosage group (group A) and 13 in the doubled dosage group (group B).
NCT00206375 ↗ Growth Hormone and GnRH Agonist in Adolescents With Acquired Hypothyroidism Completed Eli Lilly and Company Phase 4 2003-05-01 The purpose of this study is to see if giving growth hormone and Lupron along with thyroid hormone will improve final height in patients with long term hypothyroidism. Lupron is a medicine which is used to delay puberty and to prevent early closure of growing bones which might increase growth potential. Growth hormone is used to restore growth rate. This study will include children with "short term" and "long term" hypothyroidism.
NCT00206375 ↗ Growth Hormone and GnRH Agonist in Adolescents With Acquired Hypothyroidism Completed TAP Pharmaceutical Products Inc. Phase 4 2003-05-01 The purpose of this study is to see if giving growth hormone and Lupron along with thyroid hormone will improve final height in patients with long term hypothyroidism. Lupron is a medicine which is used to delay puberty and to prevent early closure of growing bones which might increase growth potential. Growth hormone is used to restore growth rate. This study will include children with "short term" and "long term" hypothyroidism.
NCT00206375 ↗ Growth Hormone and GnRH Agonist in Adolescents With Acquired Hypothyroidism Completed Baylor College of Medicine Phase 4 2003-05-01 The purpose of this study is to see if giving growth hormone and Lupron along with thyroid hormone will improve final height in patients with long term hypothyroidism. Lupron is a medicine which is used to delay puberty and to prevent early closure of growing bones which might increase growth potential. Growth hormone is used to restore growth rate. This study will include children with "short term" and "long term" hypothyroidism.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Humatrope

Condition Name

Condition Name for Humatrope
Intervention Trials
Turner Syndrome 2
Hyperlipidemia 1
Pituitary Insufficiency 1
Diabetes 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Humatrope
Intervention Trials
Dwarfism 3
Dwarfism, Pituitary 3
Gonadal Dysgenesis 2
Turner Syndrome 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Humatrope

Trials by Country

Trials by Country for Humatrope
Location Trials
Canada 7
United States 5
Netherlands 1
France 1
Italy 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Humatrope
Location Trials
Maryland 2
New York 1
Texas 1
Pennsylvania 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Humatrope

Clinical Trial Phase

Clinical Trial Phase for Humatrope
Clinical Trial Phase Trials
Phase 4 1
Phase 3 5
Phase 2/Phase 3 1
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Humatrope
Clinical Trial Phase Trials
Completed 10
Withdrawn 1
Enrolling by invitation 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Humatrope

Sponsor Name

Sponsor Name for Humatrope
Sponsor Trials
Eli Lilly and Company 9
University Health Network, Toronto 2
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Humatrope
Sponsor Trials
Industry 10
Other 6
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
AstraZeneca
McKinsey
Colorcon
Express Scripts
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.